Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
Capitalization:- Market Cap: $84.62922 billion
- Outstanding Shares: 1,735,272,000
Average Prices:- 50 Day Moving Avg: $45.37
- 200 Day Moving Avg: $43.20
- 52 Week Range: $36.76 - $49.30
P/E:- Trailing P/E Ratio: 50.442
- Foreward P/E Ratio: 17.47
- P/E Growth: 1.760
Sales & Book Value:- Annual Revenue: $22.3 billion
- Price / Sales: 3.78
- Book Value: $18.07 per share
- Price / Book: 2.69
Dividend:- Annual Dividend: $1.06
- Dividend Yield: 2.2%
Profitability:- EBIDTA: $4.77 billion
- Net Margins: 6.74%
- Return on Equity: 14.91%
- Return on Assets: 6.91%
Debt:- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.91%
- Quick Ratio: 2.31%
Misc:- Average Volume: 6.59 million shs.
- Beta: 1.08
- Short Ratio: 2.01
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, June 9th. Stockholders of record on Friday, July 14th will be given a dividend of $0.265 per share on Tuesday, August 15th. This represents a $1.06 annualized dividend and a dividend yield of 2.18%. The ex-dividend date is Wednesday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, April, 19th. The company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.43 by $0.05. The business had revenue of $6.34 billion for the quarter, compared to analyst estimates of $6.16 billion. Abbott Laboratories had a net margin of 6.74% and a return on equity of 14.91%. The firm's revenue was up 29.7% compared to the same quarter last year. During the same period last year, the company posted $0.41 earnings per share. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY17 earnings guidance on Wednesday, April, 19th. The company provided earnings per share (EPS) guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.45.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
12 brokerages have issued 12 month target prices for Abbott Laboratories' shares. Their predictions range from $42.00 to $56.00. On average, they expect Abbott Laboratories' stock price to reach $50.18 in the next year. View Analyst Ratings for Abbott Laboratories.
What are analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (6/21/2017)
- 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Medtronic PLC (MDT), Intuitive Surgical (ISRG), Align Technology (ALGN), ResMed (RMD), Varian Medical Systems (VAR), Globus Medical (GMED), NovoCure Limited (NVCR), The Spectranetics Corporation (SPNC), Integer Holdings (ITGR), Lantheus Holdings (LNTH), AxoGen (AXGN), Corindus Vascular Robotics (CVRS), T2 Biosystems (TTOO), Edap Tms S.A. (EDAP), Digirad Corporation (DRAD), Hansen Medical (HNSN) and Sunshine Heart (SSH).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.64%), Massachusetts Financial Services Co. MA (0.00%), Wellington Management Group LLP (0.00%) and Bank of New York Mellon Corp (1.96%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Pzena Investment Management LLC, FMR LLC, SG Americas Securities LLC, Macquarie Group Ltd., APG Asset Management N.V., Camber Capital Management LLC and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, State Street Corp, Boston Partners, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $48.57.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $50.18 (3.32% upside) |
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/21/2017 | BTIG Research | Initiated Coverage | Buy | $56.00 | Low |  |
| 6/16/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $55.00 | Low | |
| 5/31/2017 | Stifel Nicolaus | Boost Price Target | Buy | $49.00 -> $51.00 | Medium | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $45.00 | Low | |
| 5/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | Low | |
| 4/22/2017 | Cowen and Company | Reiterated Rating | Outperform | $48.00 | Medium | |
| 4/20/2017 | Barclays PLC | Boost Price Target | Overweight -> Overweight | $50.00 -> $52.00 | Low | |
| 4/19/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $42.00 | Low | |
| 3/14/2017 | BMO Capital Markets | Downgrade | Outperform -> Market Perform | $48.00 | Medium | |
| 9/19/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 8/9/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 7/28/2016 | Argus | Reiterated Rating | Buy | $55.00 | N/A | |
| 6/21/2016 | Edward Jones | Upgrade | Hold -> Buy | | N/A | |
| 6/8/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 5/12/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 4/30/2016 | S&P Equity Research | Reiterated Rating | Hold | | N/A | |
| 4/30/2016 | Gabelli | Reiterated Rating | Buy | | N/A | |
| 4/28/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 4/14/2016 | First Global | Downgrade | Outperform -> Marketperform | | N/A | |
| 3/28/2016 | Leerink Swann | Boost Price Target | Market Perform | $37.00 -> $40.00 | N/A | |
| 1/29/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $46.00 -> $42.00 | N/A | |
| 1/29/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 6/22/2015 forward)
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/20/2017 | | | | | | | | |
| 4/19/2017 | 3/31/2017 | $0.43 | $0.48 | $6.16 billion | $6.34 billion | View | N/A | |
| 1/25/2017 | Q416 | $0.64 | $0.65 | $5.41 billion | $5.33 billion | View | Listen | |
| 10/19/2016 | Q316 | $0.58 | $0.59 | $5.29 billion | $5.30 billion | View | Listen | |
| 7/20/2016 | Q216 | $0.53 | $0.55 | $5.24 billion | $5.30 billion | View | Listen | |
| 4/20/2016 | Q116 | $0.39 | $0.41 | $4.77 billion | $4.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.61 | $0.62 | $5.31 billion | $5.20 billion | View | Listen | |
| 10/21/2015 | Q315 | $0.53 | $0.54 | $5.16 billion | $5.15 billion | View | Listen | |
| 7/22/2015 | Q215 | $0.50 | $0.52 | $5.15 billion | $5.20 billion | View | Listen | |
| 4/22/2015 | Q115 | $0.42 | $0.47 | $4.85 billion | $4.90 billion | View | Listen | |
| 1/29/2015 | Q414 | $0.68 | $0.71 | $5.48 billion | $5.36 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.60 | $0.62 | $5.62 billion | $5.10 billion | View | Listen | |
| 7/16/2014 | Q214 | $0.51 | $0.54 | $5.53 billion | $5.55 billion | View | Listen | |
| 4/16/2014 | Q114 | $0.36 | $0.41 | $5.29 billion | $5.24 billion | View | Listen | |
| 1/22/2014 | Q413 | $0.58 | $0.58 | $5.72 billion | $5.66 billion | View | Listen | |
| 10/16/2013 | Q313 | $0.52 | $0.55 | $5.46 billion | $5.37 billion | View | Listen | |
| 7/17/2013 | Q2 2013 | $0.44 | $0.46 | $5.53 billion | $5.45 billion | View | Listen | |
| 4/17/2013 | Q1 2013 | $0.41 | $0.42 | $5.42 billion | $5.38 billion | View | Listen | |
| 1/23/2013 | Q4 2012 | $1.50 | $1.51 | $10.58 billion | $10.80 billion | View | Listen | |
| 10/17/2012 | | $1.28 | $1.30 | | | View | N/A | |
| 7/18/2012 | | $1.22 | $1.23 | | | View | N/A | |
| 4/18/2012 | | $1.00 | $1.03 | | | View | N/A | |
| 1/25/2012 | | $1.44 | $1.45 | | | View | N/A | |
| 10/19/2011 | | $1.17 | $1.18 | | | View | N/A | |
| 7/20/2011 | | $1.12 | $1.12 | | | View | N/A | |
| 4/20/2011 | | $0.90 | $0.91 | | | View | N/A | |
| 1/26/2011 | | $1.29 | $1.30 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Abbott Laboratories (NYSE:ABT)2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.85
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.43 | $0.50 | $0.45 |
| Q2 2017 | 2 | $0.60 | $0.61 | $0.61 |
| Q3 2017 | 2 | $0.64 | $0.68 | $0.66 |
| Q4 2017 | 2 | $0.72 | $0.73 | $0.73 |
| Q1 2018 | 1 | $0.56 | $0.56 | $0.56 |
| Q2 2018 | 1 | $0.71 | $0.71 | $0.71 |
| Q3 2018 | 1 | $0.74 | $0.74 | $0.74 |
| Q4 2018 | 1 | $0.84 | $0.84 | $0.84 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Abbott Laboratories (NYSE:ABT)| Next Dividend: | 8/15/2017 |
| Annual Dividend: | $1.06 |
| Dividend Yield: | 2.18% |
| Dividend Growth: | 22.90% (3 Year Average) |
| Payout Ratio: | 110.42% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.13% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/9/2017 | quarterly | $0.27 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.27 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.27 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.10%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
| Source: |
|
| Date | Headline |
|---|
 | BTIG Transition Abbott Labs (ABT) at Buy - StreetInsider.com
www.streetinsider.com - June 21 at 3:37 PM |
 | Abbott Hosts Conference Call for Second-Quarter Earnings
finance.yahoo.com - June 21 at 3:37 PM |
| Abbott Laboratories :ABT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 3:18 PM |
 | Abbott Laboratories (ABT) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 18 at 7:18 AM |
| Abbott Laboratories (ABT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 17 at 7:52 PM |
| Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak - Yahoo Finance
finance.yahoo.com - June 17 at 3:16 PM |
| Abbott Laboratories (ABT) Insider Sells $26,479.44 in Stock
www.americanbankingnews.com - June 16 at 7:58 PM |
| 2 Solid Medical Device Stocks to Scoop Up Right Away
finance.yahoo.com - June 16 at 3:32 PM |
| Abbott Laboratories (ABT) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - June 16 at 8:10 AM |
| Alere says feds won’t take action in billing probe
finance.yahoo.com - June 15 at 3:27 PM |
| Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak
finance.yahoo.com - June 15 at 3:27 PM |
| The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and Ross Stores
finance.yahoo.com - June 15 at 3:27 PM |
| ETFs with exposure to Abbott Laboratories : June 15, 2017
finance.yahoo.com - June 15 at 3:27 PM |
| Top Stock Reports for United Technologies, Abbott, Delta Air & Others
finance.yahoo.com - June 14 at 3:16 PM |
| Abbott Laboratories (ABT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - June 13 at 1:32 PM |
| Abbott Laboratories Saw a Recent Breakout
finance.yahoo.com - June 12 at 3:34 PM |
| Abbott Declares 374th Consecutive Quarterly Dividend
finance.yahoo.com - June 9 at 8:23 PM |
| AbbVie Ordered by Jury to Pay $15 Million to Depakote Victim
finance.yahoo.com - June 9 at 8:23 PM |
| Abbott Labs Declares Quarterly Dividend
finance.yahoo.com - June 9 at 8:23 PM |
| Abbott Laboratories (ABT) Insider Stephen R. Fussell Sells 196,550 Shares
www.americanbankingnews.com - June 9 at 7:31 PM |
| Abbott Laboratories (ABT) to Issue $0.27 Quarterly Dividend
www.americanbankingnews.com - June 9 at 2:26 PM |
| Abbott Laboratories (ABT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 9 at 7:46 AM |
| Birmingham health exec enters governor's race
finance.yahoo.com - June 7 at 3:20 PM |
| Abbott Laboratories at 52-Week High on Product Line, Buyouts
finance.yahoo.com - June 5 at 1:15 PM |
 | Medical Equipment Stocks on Investors' Radar -- Abbott Labs, Boston Scientific, Medtronic, and EnteroMedics
www.bizjournals.com - June 2 at 3:27 PM |
| The Zacks Analyst Blog Highlights: McCormick & Company, S&P Global, Sherwin-Williams, 3M and Abbott Laboratories
finance.yahoo.com - June 2 at 3:27 PM |
| Analysts Anticipate Abbott Laboratories (ABT) Will Post Quarterly Sales of $6.63 Billion
www.americanbankingnews.com - June 2 at 11:58 AM |
 | Insider Bets Paying Off At ABT As New 52-Week High Reached
www.nasdaq.com - June 2 at 1:22 AM |
| $0.60 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 31 at 8:30 PM |
 | Abbott Hangs On For New HeartMate Model Amid Recall - Seeking Alpha
seekingalpha.com - May 31 at 3:17 PM |
| Abbott Laboratories (ABT) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 31 at 2:36 PM |
| Abbott Laboratories (ABT) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - May 31 at 8:40 AM |
| Abbott Labs (ABT) PT Raised to $51 at Stifel Following HQ Visit with Management; 'Early Signs of Rhythm Management ... - StreetInsider.com
www.streetinsider.com - May 30 at 8:20 PM |
| This May Be The Start Of Abbott Laboratories' Upside Trajectory For 2017
seekingalpha.com - May 30 at 3:19 PM |
| Abbott Is Expected to Report a Modest Rise in Net Profit Margins
finance.yahoo.com - May 30 at 3:19 PM |
| Global Markets May Drive Established Pharmaceuticals Growth
finance.yahoo.com - May 29 at 3:17 PM |
| Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 29, 2017
finance.yahoo.com - May 29 at 3:17 PM |
| Emerging Markets Drive Abbott’s Nutritional Business Growth
finance.yahoo.com - May 26 at 3:15 PM |
| Abbott Continues to Expand Its Diagnostics Portfolio in 2017
finance.yahoo.com - May 26 at 3:15 PM |
| Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others
finance.yahoo.com - May 26 at 3:15 PM |
| Abbott Laboratories (ABT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 26 at 10:59 AM |
| How Will Abbott Laboratories Benefit from Its Alere Acquisition?
finance.yahoo.com - May 25 at 8:32 PM |
| The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon
finance.yahoo.com - May 25 at 3:30 PM |
| Is Medical Technology Driving the US Healthcare Industry?
finance.yahoo.com - May 25 at 3:30 PM |
 | FDA: Controller for heart pump recalled over deaths
marketbeat.com - May 24 at 6:29 PM |
| Abbott Laboratories (ABT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 24 at 9:04 AM |
| Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna
finance.yahoo.com - May 24 at 5:17 AM |
| Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - May 22 at 3:15 PM |
| Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - May 22 at 3:15 PM |
| Abbott Laboratories (ABT) Downgraded by TheStreet
www.americanbankingnews.com - May 21 at 10:34 PM |
Abbott Laboratories (ABT) Chart for Thursday, June, 22, 2017
